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Abstract 
Rationale. This meta-analysis of cell-based cardiac studies (ACCRUE) is the first 
prospectively-declared, collaborative, multinational database of individual patient data (IPD) from 
patients with ischemic heart disease treated with cell therapy.	  
Objective. We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial 
infarction (AMI). We included IPD from 12 randomized trials (ASTAMI, Aalst, BOOST, BONAMI, 
CADUCEUS, FINCELL, REGENT, REPAIR-AMI, SCAMI, SWISS-AMI, TIME, LATE-TIME; 
n=1252).	  
Methods and Results. The primary endpoint was freedom from combined major adverse cardiac and 
cerebrovascular events (MACCE; including all-cause death, re-AMI, stroke, and target vessel 
revascularization). The secondary endpoint was freedom from hard clinical endpoints (death, re-AMI, 
or stroke), assessed with random-effects meta-analyses and Cox regressions for interactions. 
Secondary efficacy endpoints included time-related changes in individual end-diastolic volume 
(ΔEDV), end-systolic volume (ΔESV), and ejection fraction (ΔEF), analyzed with random-effects 
meta-analyses and analysis of covariance. We reported weighted mean differences between cell 
therapy and control groups. Cell therapy results were similar to control results, based on MACCE 
(14.0% vs. 16.3%, hazard ratio 0.86, 95%CI: 0.63, 1.18), death (1.4% vs. 2.1%), death/re-AMI/stroke 
(2.9% vs. 4.7%), ΔEF (mean difference: 0.96%, 95%CI: -0.2, 2.1), ΔEDV, and ΔESV. These results 
were not influenced by anterior AMI location, a reduced baseline EF, or the use of MRI for assessing 
left ventricular parameters. 	  
Conclusions. This meta-analysis of IPD from randomized trials in patients with recent AMI revealed 
that intracoronary cell therapy provided no benefit, in terms of clinical events or changes in left 
ventricular function.	  
 
Clinical trial registration: clinicaltrials.gov_NCT01098591	  
Key words: stem cell, acute myocardial infarction, meta-analysis, heart failure, outcome	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Non-standard Abbreviations and Acronyms:	  
ACCRUE: Meta-Analysis of Cell-based CaRdiac stUdiEs	  
AMI: acute myocardial infarction	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BM-MNCs: bone marrow mononuclear cells	  
CI: confidence interval	  
CK: creatine kinase	  
DM: diabetes mellitus	  
EDV: end-diastolic volume	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ESV: end-systolic volume	  
FUP: follow-up	  
HR: hazard ratio	  
iCMP: ischemic cardiomyopathy	  
IDC: Independent Data Committee	  
IHD: ischemic heart disease	  
IPD: individual patient data	  
LV: left ventricular	  
MACCE: major adverse cardiac and cerebrovascular events	  
MRI: magnetic resonance imaging	  
PI: principal investigator	  
SD: standard deviation	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STEMI: ST-segment elevation myocardial infarction	  
TVR: target vessel revascularization	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Meta-analyses of randomized and cohort cell therapy studies have reported that intracoronary 
or intramyocardial cell delivery was safe, and it provided 2-8% increases in global, left ventricular 
(LV) ejection fraction (EF) in patients with acute myocardial infarction (AMI) or ischemic 
cardiomyopathy.1-4 Those meta-analyses were based on information from studies that included 
different patient populations, follow-up (FUP) times, and outcome measures. Consequently, the meta-
analysis interpretations were heterogeneous, due to inconsistent clinical definitions and parameters. 
Additionally, publication-based meta-analyses may include studies that were later withdrawn or that 
contained publication errors,5 and they may exclude important trials that reported median values of 
skewed data. In contrast, individual patient data (IPD)-based meta-analyses contain transparent, 
controlled data, with unique definitions; this approach allows analyses of specific subgroups and 
generation of prognostic models. 	  
The largest previous relevant meta-analysis enrolled 50 studies (n=2625 patients). They 
reported that cardiac transplantation of adult bone-marrow-derived cells (BMCs) provided persistent 
benefits, in terms of clinical outcome and LV parameters.3 However, a recent meta-analysis on 
intracoronary cell treatment trials, which included 30 studies (n=2037 patients), could not confirm data 
obtained from magnetic resonance imaging (MRI) measurements of LV function4; moreover, they 
were the first to report that cell therapy had no effect on clinical outcome. Both meta-analyses used 
aggregated data from published studies, but there was considerable heterogeneity across the trials 
involved. 	  
The ongoing, meta-analysis of cell-based cardiac studies (ACCRUE, NCT01098591, formerly 
MEta-analysis of Stem cell Studies, MESS) is based on a collaborative, multinational database that 
comprises IPDs from randomized and cohort studies. The ACCRUE database was established to 
facilitate exploration of the clinical safety and efficacy of cell therapy in patients with ischemic heart 
disease (IHD) and to identify subgroups of patients predicted to benefit from cell therapy. The present 
study represents the first IPD-based meta-analysis of cell treatment in IHD to date.	  
The objectives of this ACCRUE study were:	  
1. To estimate the overall treatment effect of cardiac cell-based therapy on clinical outcomes, 
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including occurrence of major adverse cardiac and cerebrovascular events (MACCE, composite of all-
cause death, AMI recurrence [re-AMI], coronary target vessel revascularization [TVR], and stroke) 
and the occurrence of clinical hard endpoints (death, re-AMI, or stroke);	  
2. To analyze the effect of cell therapy treatment on LV function and remodeling, including changes in 
end-diastolic volume (EDV), end-systolic volume (ESV), and EF;	  
3. To identify predictors of MACCE and of LV function and remodeling improvements in patients 
with IHD treated with cell therapy;	  
4. To explore the influence of patient characteristics, including cardiovascular risk factors, on the 
safety and efficacy of cardiac cell therapy;	  
5. To identify the characteristics of individual patients with IHD that can predict benefit from cell 
therapy.	  
Methods 
The main objective of the ACCRUE group is to use IPDs to improve the quality of data used 
in meta-analyses of cell therapy studies in patients with chronic IHD and AMI. The first collaborative 
meeting was held in Vienna, 2007, with the investigators of the ASTAMI, REGENT, BOOST, Aalst 
(Bartunek)-study, BONAMI, REPAIR-AMI, Atsma-study, MYSTAR, STEMMI, the Hamburg and 
Novosibirsk intramyocardial studies, and the EUROINJECT-ONE cardiac gene therapy study. The 
meeting aimed to define objectives, to establish data contribution criteria, and to appoint the 
Independent Data Committee (IDC) and Steering Committee (Online Supplementary Data). 	  
Criteria for considering studies for inclusion in the ACCRUE database 
The criteria for contributing data to the ACCRUE database were that the data must be from 
randomized or cohort clinical studies, and that cardiac regeneration was induced by percutaneous 
administration of cells- or cell-based products, or by mobilization of BMCs. A continuous literature 
search was initiated, and principal investigators and study coordinators of recently published studies 
were prospectively invited to contribute IPDs to the database. Additional study inclusion criteria for 
randomized studies are included in the Online Supplementary Data. 	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Outcome measures 
The primary outcome measure of the ACCRUE meta-analysis was the safety of the treatment, 
defined as the freedom from MACCE (the composite of all-cause death, re-AMI, stroke, and TVR). 
The secondary endpoints were freedom from the combined hard clinical endpoints (all-cause death, re-
AMI, or stroke) or freedom from the individual components of MACCE. Another secondary endpoint 
was efficacy, defined as changes in LV, EDV, ESV, and EF, compared to baseline.	  
Search methods for identifying studies 
Studies were prospectively identified in literature searches, and the identified investigators 
were invited to participate. The search methods are included in the Online Supplementary Data. 	  
Data collection and management 
The data collection method is described in the Online Supplementary Data. The corresponding 
authors and primary investigators of selected studies were emailed or contacted personally several 
times with invitations to contribute original data to the central database (Fig. 1). Participants deposited 
the individual data into the database, which was prepared with predefined terms and conditions 
(determined and agreed upon at the first investigator meeting). Authors from 39 centers responded, 
and data were received from 23 centers6-17 (additional references in Online Supplementary Data, 
References 18-28). One center later cancelled participation and withdrew their data, due to changes in 
institutional policy. The current ACCRUE database comprises 1871 IPD sets from 28 studies (15 
randomized studies, 10 cohort cell therapy studies, and 3 studies with granulocyte-colony stimulating 
factor). All patients were classified as “cell-treated” (n=1203) or  “control” (n=668).  	  
In accordance with pre-specified plans, analyses carried out in ACCRUE differ from those 
carried out in the individual papers. Therefore, results from the ACCRUE report may be different from 
those reported in the individual papers, particularly when different terms were used for event 
classifications or FUP times. These issues were discussed with the corresponding authors of all papers. 	  
All studies were approved by the local ethics committees. Additional approval was obtained 
for the meta-analysis. Data quality was evaluated with quality checklists provided in the CONSORT18 
and PRISMA (http://www.prisma-statement.org) statements and guidelines.	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The database was controlled by the IDC. It was temporarily closed in June, 2014, to perform 
the first statistical analysis. The current meta-analysis included data from patients with recent AMIs 
that were randomized to either intracoronary cell-therapy or control therapy (ASTAMI, Aalst, 
BONAMI, BOOST, CADUCEUS, FINCELL, LATE-TIME, REGENT, REPAIR-AMI, SWISS-AMI, 
TIME, SCAMI trials).6-17  The present analysis excluded all non-controlled studies, the MYSTAR 
study, which included a combined delivery mode in patients with recent AMI, and all randomized 
percutaneous intramyocardial cell-based studies in patients with chronic IHD (Fig. 1).	  
Assessment of risk of bias in included studies 
Methods for assessing the risk of bias and quality of the studies are described in the Online 
Supplementary Data. 	  
Statistics 
This IPD-meta-analysis was conducted in accordance with the Cochrane Handbook for 
Systematic Reviews of Intervention19 and the guidelines for meta-analysis of IPD for time-to-event 
outcomes.20,21 Heterogeneity between the studies was tested with I2 statistics. Additional sensitivity 
analyses were performed to detect differences between studies. Two investigators conducted the 
analyses (EN, MG).	  
Investigation of heterogeneity and selection bias 
The statistics for investigating heterogeneity and selection bias of the included trials are 
presented in the Online Supplementary Data. 	  
General Statistics	  
Normally-distributed, continuous variables are presented as the mean±standard deviation 
(SD). Continuous parameters with skewed distributions are expressed as the median and first 
interquartile range. Binary and categorical variables are given as frequencies and percentages. 
Associations between the number of cells/log number of cells and the changes in EDV, ESV, or EF in 
the cell-treated group were calculated with linear regression analysis. 	  
All P values were based on two-sided tests. For multiple comparisons, P values less than 0.01 
were considered statistically significant.	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IPD meta-analysis 
All analyses were based on the intention to treat. Multiple Cox regression models were used to 
analyze the primary outcome, stratified for the individual studies. The multiple model included 
cardiovascular prognostic factors for the occurrence of MACCE, such as gender, age, diabetes 
mellitus (DM), hypertension, hyperlipidemia, and baseline EDV and EF values. This model was used 
to determine an adjusted, common treatment effect, with baseline hazards that varied across 
studies.20,21 To evaluate possible dependencies of the treatment effect on other prognostic factors, all 
possible interactions were tested within the multiple stratified Cox regression models. Factors were 
excluded from the analysis when data were missing in at least 50% of cases (e.g., positive family 
anamnesis for heart disease, baseline infarct size). Adjusted HRs and their 95% CIs are presented with 
the corresponding P values. The Kaplan-Meier method and cumulative hazards were used to display 
the MACCE-free, death-free, death/re-AMI/stroke-free, and TVR-free survival rates. Pre-specified 
subgroup analyses for the primary endpoint and the secondary endpoint of death/re-AMI/stroke were 
carried out for the following subgroup categories: age (> or ≤ 57 years), EF (> or ≤45%), baseline 
EDV (> or ≤130 ml), anterior AMI (yes or no), maximal creatine kinase (CK, > or ≤ 3450 U/l; CK is 
associated with infarct size; 3450 U/l was the median value for all patients), gender, DM, 
hypertension, hyperlipidemia, smoking, and use of MRI.  	  
 The secondary endpoints, changes in LV EF, EDV, and ESV, were evaluated with an analysis 
of covariance (ANCOVA). The treatment effect was adjusted for cardiovascular risk factors, male 
gender, mode of measuring LV function, anterior location of AMI, baseline EDV, baseline EF, and 
time between AMI and randomization (sham intervention in controls or cell therapy in cell-treated 
groups); for these adjustments, the individual studies were considered a block factor. Possible 
interacting effects with treatment were tested within these ANCOVA models. Changes in EDV, ESV, 
and EF in the cell therapy and control groups are expressed as the mean ±SD; the mean difference 
from baseline was reported with the SE, and the relative 95% CIs were reported as effect measures. 	  
Pre-specified subgroup analyses included the effect of FUP time and the effect of baseline EF 
on changes in LV function, evaluated as dichotomous variables. The numbers of patients in groups 
that received different subtypes of autologous cells were uneven or low; therefore, we did not perform 
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subgroup analyses on the effect of cell types on the endpoints.	  
All statistical computations were performed with Review Manager 5.2 (The Nordic Cochrane Center, 
Købehvn, Denmark) and Stata/SE, version 12, for Windows (StataCorp, Houston, Texas).	  
Results 
Search results 
A systematic search for eligible trials resulted in 1533 clinical reports on cardiac cell 
therapies. Of these, 921 were excluded based on the pre-clinical nature of the studies or  because they 
were only abstracts or incomplete reports. Thus, 612 clinical studies were eligible, and 149 were 
selected because they used cell injections or autologous BMC mobilization. A further 94 studies were 
excluded because they were reviews, descriptions of surgical approaches, or pilot studies for study 
designs or sub-analyses. Finally, 55 studies were included, and the corresponding authors were 
contacted. The present analysis included 12 randomized studies on intracoronary cell therapy applied 
after AMI (Fig. 1).	  
Study characteristics 
Table 1 lists the study characteristics. An average of 104 patients was included in individual 
studies (n=64 and n=40 for cell treatment and control groups). Most studies used BM mononuclear 
cells (BM-MNCs), and MRI was used for visualizing and quantifying LV performance. Three studies 
assessed the timing of cell therapy (CADUCEUS, LATE-TIME, SWISS-AMI); otherwise cell 
therapies were performed within 2 weeks post-AMI. Most patients were randomized during the first 
week (65% of patients in the cell-therapy and 79% of patients in the control group), and EF was 
measured before randomization. The quantitative baseline LV functional parameters were assessed at 
the time of the primary PCI (e.g., FINCELL), before randomization, 1-3 days post-AMI (e.g., 
REGENT), or several weeks post-AMI, after resolution of myocardial stunning (e.g., LATE-TIME). 
Thus, there were different time lapses between the delivery of cell therapy and the measurement of 
baseline LV function.	  
All patients received clinical FUPs. Paired LV functional data measured at baseline and at 
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FUP were available for 1064 (624 cell-therapy and 440 control) patients. Baseline LV function and 
FUP events were not different for patients that lacked paired LV data for any reason (data not shown). 	  
Infarct size data were available for 114 of 767 subjects (14.9%) that received cell-therapy and 
for 111 of 485 subjects (22.9%) in the control group. Because these groups did not represent the entire 
population, we did not analyze changes in infarct size.	  
Study quality and risk of bias in included studies 
Online Table I shows the scales for assessing the quality of the studies on randomized 
intracoronary cell therapy in AMI that were included in the ACCRUE database. The internal validity 
was based on results from the external validity criteria and sensitivity analyses; these are described in 
the Online Supplementary Data. 	  
Baseline patient characteristics 
Table 2A shows the baseline clinical data, including measurements of baseline LV function 
parameters. No differences were observed between the two groups, with the exception of ESV, which 
was lower in controls. Cardiac MRI was more often used as the imaging modality in the cell therapy 
group, due to the higher number of patients in cell-therapy group than in the control groups of the 
SWISS-AMI and REGENT trials (2:1 randomization).	  
Primary endpoint  
MACCE was similar between the groups (HR: 0.86, 95% CI: 0.63, 1.18; Table 2B, Online  
Figure I). After adjusting for all confounding factors, the Cox regression showed no effect of cell-
therapy on MACCE-free survival (Table 2B, Figure 2). The addition of anterior AMI as a confounding 
factor did not influence the primary outcome (Online Table II). The subgroup analysis did not reveal a 
prognostic factor for prevention of MACCE (Fig. 2); therefore, we found no factors that influenced the 
success of cell therapy.	  
The results of the overall meta-analysis (between-trial analyses) for the primary endpoint were 
highly consistent in direction and magnitude with those obtained from the individual participant data 
meta-analyses (within-trial analyses); i.e., there was no significant benefit with cell therapy vs. 
controls (HR: 0.86, 95% CI:0.63, 1.18; P=0.884). No significant heterogeneity or inconsistency was 
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found between trials (I2=0%) (Online  Figure I). Additionally, the funnel plot for the primary endpoint 
did not show asymmetry on visual inspection (Online  Figure I), which was confirmed by a non-
significant Egger’s test. 	  
Secondary endpoints 
Similar to the primary endpoint, cell therapy did not improve clinical outcome in terms of the 
incidence of death, death/re-AMI/stroke, and TVR (Table 2B, Fig. 3A, Online Figure II). No 
cardiovascular risk factor could be identified that influenced the clinical hard end points  (death/re-
AMI/stroke). Similarly, the hard endpoints were not impacted by a lower baseline EF, a higher EDV, 
the location of infarction, the maximal CK, or whether LV function was measured with MRI. 
Although we observed a trend that different subgroups showed different directions in the effect of cell 
therapy, as shown in the forest plot (Figure 3B), none was consistently significant (p>0.01), and no 
interaction was significant. 	  
Both EDV and EF increased slightly in cell-treated and control groups (Table 2B), without a 
decrease in ESV from baseline to FUP. Cell therapy did not influence the changes in global EF (mean 
between-group difference of 0.96%, 95% CI: -0.2 2.1), EDV (1.2 ml, 95% CI:-3.4. 5.8), or ESV (0.4 
ml, 95% CI: -3.4, 4.1) (Table 2B, Figs. 4A, 4B, 4C).	  
 Table 3 summarizes the ANCOVA results (detailed data in Online Table III). The final 
changes in EDV, ESV, and EF were not influenced when the model included covariates of gender, 
age, DM, hypertension, hyperlipidemia, anterior AMI location, MRI imaging modality, baseline EDV, 
baseline EF, or timing of cell treatment. Cell therapy in older patients led to a greater increase in EDV 
compared to controls, with no significant changes in ESV or EF (Online Table III). 	  
Sub-analysis of different FUPs 
Four studies provided 1-year clinical FUP data (CADUCEUS, REPAIR-AMI, SWISS-AMI, 
and SCAMI); the other studies reported clinical FUPs of 6 months or shorter. No difference between 
the groups was identified at the 6-month FUPs or at the 6-to-12-month FUPs regarding MACCE, 
death, death/re-AMI/stroke, or TVR (Online Figures III-V). The majority of MACCE events were 
TVR at the 6-month FUP. Trials with a planned 6-month clinical FUP controlled the patients and 
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performed TVR when in-stent restenosis of the infarct-related artery was documented. This resulted in 
an increase in the TVR incidence at 6 months, but there was no difference between groups. 	  
 Most of the LV functional measurements were performed at the 6-month FUP; the Aalst-
study, BONAMI, and REPAIR-AMI provided 3- or 4-month FUP data; the CADUCEUS and SCAMI 
studies also had control measurements at 1 year. Table 4A shows the FUP time-dependent changes in 
LV EDV, ESV, and EF in cell-treated and control groups. An increase was observed in EDV from 
baseline to the 6-month and 12-month FUPs in both the cell-therapy and control groups. Due to the 
relatively low numbers of patients in these subgroups, and to avoid a type I error, we did not performs 
statistical comparisons between the 6- and 12-month FUP data. No difference between groups was 
detected regarding FUP data collected at ≤6 months, or >6 months.	  
Sub-analysis of baseline EF effects on changes in LV parameters 
The sub-classes of baseline EF (>50%, >45%, and >40%) showed no influence of baseline EF 
on the changes in EDV, ESV, or EF at the FUP (Table 4B).	  
Effect of the number of injected cells on LV function 
Linear regression analysis showed no correlation between the number of injected cells or the 
log number of injected cells and the changes in EDV, EF (Online Figure VI), or ESV (data not shown) 
in the cell-treated group. There was, however, a large scatter in the number of  cells applied (range: 
12.5-4303 × 106). 	  
Comparison of ACCRUE data with results from non-participating studies 
Online Table IV summarizes the results from currently published randomized cell-therapy 
trials in patients with recent AMI that did not contribute to the ACCRUE database. The reported mean 
EF± SD and the number of included patients are shown (Online Supplementary Data, References 29-
47). These 19 studies included 503 patients (mean = 27) in the cell-treated group and 352 patients 
(mean = 19) in the control group. In contrast, the ACCRUE intracoronary arm included 767 patients 
(mean = 64) in the cell-treated group and 485 patients (mean = 40) in the control group. The 
ACCRUE database currently represents over 70% of all clinical cardiac regeneration studies and 
approximately 60% of all intracoronary cell studies; it includes all major randomized studies, except 
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the HEBE trial, the Cao study, and the Chen study (Online Supplementary Data, References 36,40,45).	  
Discussion 
This ACCRUE study was based on the first IPD database, constructed for meta-analyses of 
cardiac cell therapy. The database comprised a pool of 1871 IPDs from 15 randomized cardiac 
regeneration studies. Twelve of these studies (with 1252 IPDs) involved intracoronary cell delivery in 
patients with recent AMIs. This first ACCRUE meta-analysis selected randomized studies on 
intracoronary administration of reparative cells. We found no effect of cell therapy on clinical events 
or changes in LV function or remodeling. Based on original data, we could not identify predictive 
factors or patient characteristics that might indicate patients most likely to benefit from cell therapy.	  
An important feature of this ACCRUE, which is rarely seen in other meta-analyses, was its 
prospective nature, in accordance with the Cochrane guidelines for planning and conducting an IPD 
meta-analysis, involving also the Cochrane Heart Group. The prospective data collection of ACCRUE 
allowed uniform definitions of endpoints, follow-up periods, and adverse events; this approach 
ensured the most unbiased, and thus, the most reliable results. It also increased the robustness and 
accuracy of the findings. The ACCRUE investigators met the goal of this analysis and take advantage 
of its benefits.	  
However, some caution should be taken with the interpretation of our results. The negative 
and, for the health community, disappointing results are not surprising. Six of the included studies 
(including about two thirds of the study patients), which comprised the largest and most homogeneous 
clinical populations (ASTAMI, BONAMI, REGENT, TIME, LATE-TIME, SWISS-AMI), reported no 
benefit from autologous cell-based, intracoronary regenerative treatment.8,9,11,15-17 One out of three 
similarly large studies, which were not included in the ACCRUE database (HEBE), also reported a 
negative outcome. 	  
Potentially, the efficacy of cell therapy could be affected by differences among the studies 
included in the ACCRUE database. For example, differences in the types of injected cells and the 
timing of cell administration (acute phase of AMI versus convalescent AMI) may affect the outcomes.  
We did not evaluate these factors separately, because the individual subgroups would have comprised 
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statistically unacceptably low numbers of patients, and the analysis may not have provided additional 
informative value. However, the ANCOVA analysis showed that, when the time to cell/control 
therapy was considered as an independent covariate, it did not significantly affect the changes in EDV, 
ESV, or EF. An additional factor that might influence changes in LV function could be the time that 
baseline EF was measured (if not the same day as the cell therapy). This timing may be consequential, 
considering that, in the natural course of the reperfused AMI, during the first week, rapid changes 
were observed in the EF and the size of late enhancement in serial MRIs.22 Moreover, there was a 
time-dependent component in the regenerative function of the different types of harvested autologous 
co-morbid BM-origin cells.23	  
Adverse events, LV function, and LV remodeling related to intracoronary cell therapy 
Intracoronary administration of cells proved to be safe, with a low procedural complication 
rate (2.2%). The composite in-hospital complications were similar between groups. The mortality and 
incidence of hard clinical endpoints were noticeably low among the patients with STEMI in both 
groups. This finding may have resulted from the carefully selected patients and the relatively high 
baseline EFs. Sub-analyses of different FUPs did not change the outcome difference between treated 
and control patients; the negative results were consistent. We point out that a placebo effect has been 
observed in blinded randomized trials, although this effect might be less significant than in non-
randomized studies. Because the placebo effect is additive to the control treatment effect, it can reduce 
the observed treatment effect size and the statistical power of the study. 	  
Most patients underwent MRI scanning, which is regarded the gold standard for assessing LV 
function. Similar to our results, de Jong et al. found that the beneficial effect of cell therapy on LV EF 
and infarct size disappeared, when MRI was used for quantitative imaging.4 Additionally, both studies 
found that the baseline EF did not affect the improvement in LV function over time.4 Also our data 
were consistent with a previous study, where serial cardiac MRIs of patients with reperfused, first 
AMIs showed a gradual increase in LV EDV during the first year after the AMI.22	  
In contrast with previous meta-analyses,3,4 we did not assess infarct size at FUP, because the 
majority of trials did not measure infarct size before cell therapy; therefore, no change between 
baseline and FUP could be reported. Instead, we added the maximal CK as a confounding factor that 
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could influence the outcome, because maximal CK is highly associated with infarct size.24	  
In contrast with previous meta-analyses, we found no association between the number of cells 
delivered and the outcomes. It should be mentioned, however, that the numbers of cells used for 
intracoronary cell therapy varied widely, even without considering trials that assessed the importance 
of cell number on the clinical or functional outcome. Previous studies reported only the mean or 
median numbers of injected cells/group. Therefore, the results of those analyses should be considered 
less exact than results from this ACCRUE study.	  
One of the objectives of this ACCRUE study was to reveal prognostic factors for clinical 
events or identify patients that might benefit from cell therapy. We did not achieve this objective, 
despite the fact that the intracoronary treatment arm of the ACCRUE database included large 
randomized studies (mean of 104 patients/study) with remarkably low between-trial heterogeneity, 
compared to the previous largest reported meta-analysis.3,4 Because we used common definitions of 
primary endpoints throughout the studies, the heterogeneity for clinical endpoints was 0% among 
studies. In contrast to previously published meta-analyses, which showed up to 87% heterogeneity 
among studies, our meta-analysis showed little or no heterogeneity among studies for continuous 
parameters of the secondary endpoints; i.e., the heterogeneities were 0% for ΔEDV, 11% for ΔESV, 
and 48% for ΔEF. This highlighted the accuracy of a large-scale IPD-based meta-analysis in 
characterizing any potential effect in different clinical subgroups and its pivotal role in fully exploring 
the clinical relevance and adequacy of cell therapy for treating IHD. However, according to de Jong et 
al., more than 30 000 patients should be included in a study to identify an effect of cell therapy 
treatment, when mortality is around 2%,4 similar to our findings.	  
Advantages of the IPD-based meta-analysis  
This ACCRUE IPD-based meta-analysis overcame the major limitations of systematic 
reviews and conventional meta-analyses. Those approaches extract aggregated data from available 
publications according to a predefined study protocol, and the random effects are determined by 
calculating the weighted means (e.g., relative risk) of randomized trials. Accordingly, publication-
based meta-analyses must exclude some important trials, where group differences are expressed as the 
median and interquartile range (e.g., BONAMI, HEBE, MYSTAR, REGENT). Online Table 4 shows 
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the heterogeneity among reports of LV functional data from studies that did not contribute to the 
ACCRUE database. All but one study (Ruan et al. Supplemental Reference 47) were included in a 
recent intracoronary cell therapy AMI meta-analysis.4 When no original data were available, they re-
calculated the mean differences and 95% CIs or SDs with meta-analysis software and a standardized 
formula. Thus, these re-calculated data were partially discrepant with the published or original data; 
e.g., Plewka et al. showed changes in EF from baseline to FUP of 10±9% in the cell-therapy group vs. 
5±8%  in controls (Supplemental Reference 35); in contrast; the calculated random-effect meta-
analysis data showed EF changes of 9±5.8 vs. 5±4.9% or 9±7% vs. 5±3.4%, respectively.3,4  
Alternatively, the present IPD meta-analysis included raw data; thus, we could calculate accurate, real 
means with SDs, mean differences with SEs, and CIs; moreover, these calculations were not 
influenced by the limited information gained from the publications. 	  
Limitations of the ACCRUE database 
 A major limitation of the present study was the combination of several different cell types 
(BM-MNCs, CD133+ -enriched BMCs, CD34+CXCR selected cells, or cardiosphere-derived cells 
[CDCs]). As in all previous meta-analyses, we assumed that the potency was comparable among 
different cell types . In fact, different cell populations exert heterogeneous effects, depending on the 
amount of time passed since the AMI.23 Additionally, when various clinically-utilized cell types were 
compared directly in the same mouse infarct model, the rank order of efficacy was CDCs>>BM-
MNCs.25 Only 2% of the ACCRUE database comprised heart-derived cells; thus, heart cells were not 
well-represented in the present analysis. Additionally, intracoronary infusion of allogeneic 
mesenchymal stem cells resulted in a 6.28% increase in EF, as reported by de Jong et al.4 Our meta-
analysis contained only studies with autologous cells, which in turn, increased its homogeneity. 	  
Another limitation was that the IPD in the ACCRUE database included fewer studies and 
patients than the total number of available published studies. Thus, this study did not include all 
studies that would be typically incorporated into a conventional meta-analysis. This lack was partly 
due to centers that refused to provide individual data and partly due to the temporary closure of the 
database, which precluded studies that were published later.  
Most previous large medical IPD-based meta-analysis studies were company sponsored. 
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Those studies implemented a generalized electronic case report form, and the database and data were 
monitored by external monitoring companies. Therefore, extraction of standardized data from case 
report forms was a priori facilitated. However, to date, no company-sponsored studies on cell-based 
cardiac regeneration with intracoronary cell delivery have been conducted and controlled centrally. At 
the time the present study was initiated, no financial support was available for the effort of providing 
and formatting data in accordance with the ACCRUE database. Additionally, data that did not 
represent the entire population could not be assessed; we could only analyze data on specific 
information collected for the database, such as medications during FUP, or specific information 
provided by the centers, such as data on stent thrombosis. However, the statistical analysis revealed a 
remarkably low heterogeneity across the trials included in this ACCRUE study (I2 0% to 48%), 
compared to previous, largest meta-analyses (I2 up to 87%),3,4 due to the pre-specified baseline and 
outcome parameters.  
The results of this IPD meta-analysis revealed some important discrepancies from previous 
meta-analyses. Our findings highlighted the lack of consistent efficacy in cell-based cardiac 
regeneration with intracoronary cell delivery in patients with diverse cardiovascular risk factors. 
Although the ACCRUE database has continued to recruit data contributions, it cannot replace large-
volume, prospective randomized studies, such as the ongoing BAMI trial (ClinicalTrials.gov 
Identifier: NCT01569178) or the CCTRN network.26,27	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Figure legends 	  
Figure. 1. Flow diagram of the ACCRUE database and participating studies 	  
G-CSF: granulocyte colony-stimulating factor; AMI: acute myocardial infarction; iCMP: ischemic 
cardiomyopathy	  
Figure 2. Primary endpoint analysis.	  
2A. Major adverse cardiac events (MACCE)-free survival of patients with recent acute myocardial 
infarction who were randomized to either cell therapy or control treatment (upper). Hazard ratio and 
95% confidence intervals of risk factors that favor cell therapy or control treatment (bottom). MACCE 
defined as all-cause death, re-infarction, target vessel revascularization, and stroke; DM: diabetes 
mellitus; EDV: end-diastolic volume, EF: ejection fraction	  
2B. Forest plot of MACCE-free survival in subgroups, with hazard ratio (Haz), CI: confidence 
interval, P inter: P for interaction, CK:creatine kinase, MRI: magnetic resonance imaging	  
Figure 3. Secondary endpoint analysis.	  
3A. Kaplan-Meier analysis of death/AMI/stroke–free survival of patients randomized either to cell-
therapy or controls (upper). Hazard ratio and 95% confidence intervals of risk factors favoring cell 
therapy or control treatment (bottom). AMI: acute myocardial infarction, DM: diabetes mellitus; EDV: 
end-diastolic volume, EF: ejection fraction	  
3B. Forest plot of death/AMI/stroke-free survival in subgroups with hazard ratio (Haz), CI = 
confidence interval, p inter= P for interaction, AMI: acute myocardial infarction, CK: creatine kinase, 
MRI: magnetic resonance imaging	  
3C. Kaplan-Meier analysis of target vessel revascularization (TVR)-free survival (upper). Hazard ratio 
and 95% confidence intervals of risk factors favoring cell therapy or control treatment (bottom). DM: 
diabetes mellitus; EDV: end-diastolic volume, EF: ejection fraction	  
Figure 4. Forest plot displaying changes in left ventricular ejection fraction, end-diastolic and 
end-systolic volumes in patients treated with intracoronary cell therapy after recent acute 
myocardial infarction. 	  
Unadjusted difference in mean with 95% confidence intervals	  
4A. Forest plot of changes in ejection fraction 	  
4B. Forest plot of changes in end-diastolic volumes	  
4C. Forest plot of changes in end-systolic volumes	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Table 1. Study characteristics	  	  
Name of 
Study 
Sample 
size  
(Cell 
therapy/C
ontrols) 
Mean 
follow-up 
duration 
(month) 
Cell type Location of 
AMI 
Time 
from 
AMI to 
cell 
delivery 
(days) 
Imaging 
modality 
CADUCEUS 17/8  12 Cardiosphere-
derived cells 
anterior 
(except 1) 
62±11 MRI 
BONAMI 52/49 3 BM-MNC anterior 9±2 SPECT, RNV 
Aalst Study 19/16 4 BM-MNC multiple 12±1 LV 
Angiography 
REPAIR-AMI 101/103 4 BM-MNC multiple 4±1 LV 
Angiography 
BOOST 30/30 6 BM-MNC multiple 5±1 MRI 
LATE-TIME 58/29 6 BM-MNC multiple 17±5 MRI 
ASTAMI 50/50 6 BM-MNC anterior 6±1 SPECT, 
Echocard. 
REGENT 160/40 6 BM-MNC, or 
selected 
CD34+CXCR 
anterior 7±2 MRI 
SWISS-AMI 133/67 4 BM-MNC multiple 13±10 MRI 
TIME 79/41 6 BM-MNC multiple 5±2 MRI 
SCAMI 29/13 12 BM-MNC multiple 6±1 MRI 
FINCELL 39/39 6 BM-MNC multiple 3±1 Echocard. 	  
BM-MNC: Bone marrow mononuclear cells, AMI: acute myocardial infarction, MRI: magnetic 
resonance imaging, SPECT: single photon emission computed tomography, RNV: radionuclide 
ventriculography; LV: left ventricular; Echocard.: Echocardiography	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Table 2A. Baseline data of patients with recent acute myocardial infarction (AMI) and 
randomized to cell-therapy or control	  
 Cell therapy Control P value 
 n=767 n=485  
Baseline    
Age (y) 57.3±10.4 57.0±10.7 0.600 
Male gender  614/767 (80.1%) 405/485 (83.5%) 0.136 
Diabetes mellitus  111/767 (14.5%) 79/485 (16.3%) 0.419 
Hypertension  384/767 (50.1%) 244/485 (50.3%) 0.954 
Hyperlipidemia 387/717 (54.0%) 228/435 (52.4%) 0.626 
Active smoker  396/708 (55.9%) 243/422 (57.6%) 0.620 
Maximal creatine kinase (U/L) 3467±2492 3410±2426 0.235 
Number of diseased vessels 1.3±0.6 1.3±0.6 0.952 
Anterior AMI 662/767 (86.3%) 415/485 (85.6%) 0.351 
    
Pre-cell therapy    
End-diastolic volume (ml)  146±51 139±48 0.012 
End-systolic volume (ml) 84±40 77±36 0.004 
Ejection fraction (%) 43.7±11.9 45.5±11.8 0.011 
Magnetic resonance imaging 492/767 (64.1%) 257/485 (53.0%) <0.001 
    
Cell therapy    
Time from AMI to treatment in cell 
therapy group and randomization/sham 
intervention in controls (days) 8.0±9.7 6.6±10.9 0.202 
Number of cells injected intracoronary 
(x10^6) (median and 25% and 75% 
interquartile ranges) 150 (6, 294)  
 
Intracoronary injection-related procedural 
complication (%) 14/630 (2.2%)  
 
In-hospital complication (%) 21/631 (3.3%) 21/413 (5.1%) 0.197 	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Table 2B. Primary and secondary endpoints	  
 Cell therapy Control P value 
Follow-up n=767 n=485 
 
Follow-up time (days) 225±112 231±114 0.375 
   (median with range) (180; 90-365) (180; 90-365) 
 
MACCE 107/767 (14.0%) 79/485 (16.3%) 0.289 
All-cause death (%) 11/767 (1.4%) 10/485 (2.1%) 0.499 
Target vessel revascularization (%) 87/767 (11.3%) 65/485 (13.4%) 0.287 
Death or Re-AMI or stroke 22/767 (2.9%) 23/485 (4.7%) 0.088 
Non-serious adverse events 55/680 (6.5%) 40/472 (8.5%) 0.206 
End-diastolic volume (ml)  162±57 153±54 0.008 
End-systolic volume (ml) 89±48 82±44 0.012 
Ejection fraction (%) 47.3±13.9 48.3±13.4 0.245 
    
Changes from baseline to follow-up  (n=624) (n=440) 
 
Δ End-diastolic volume (ml)  15.0±40.1 13.8±33.4 0.614 
   Mean difference (SE), 95% CI 1.2 (2.3), -3.4, 5.8  
 
Δ End-systolic volume (ml) 5.0±32.5 4.6±27.4 0.853 
   Mean difference (SE), 95% CI 0.4 (1.9), -3.4, 4.1  
 
Δ Ejection fraction (%) 3.6±9.5 2.6±8.9 0.096 
   Mean difference (SE), 95% CI 0.96 (0.58), -0.2, 2.1   	  
AMI: acute myocardial infarction, MRI: magnetic resonance imaging, MACCE: major adverse cardiac 
and cerebrovascular events, SE: standard error, CI: confidence interval.	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Table 3. Results of interaction analysis (ANCOVA models) in patients with recent acute 
myocardial infarction and randomized either to cell treatment of controls	  
  Changes in Changes in Changes in 
 
end-diastolic volume end-systolic volume ejection fraction 
Cell treatment effect 
with male gender  
p value 0.919 0.977 0.091 
   Mean difference -0.32 -0.08 1.34 
   SE (95% CI) 3.2 (-6.6, 5.9) 2.6 (-5.2, 5.1) 0.79 (-0.2, 2.9) 
  
   Cell treatment effect 
with diabetes mellitus 
p value 0.483 0.694 0.388 
   Mean difference 2.30 1.06 0.70 
   SE (95% CI) 3.3 (-4.1, 8.7) 2.7 (-4.2, 6.3) 0.8 (-0.9, 2.3) 
  
   Cell treatment effect 
with hypertension 
p value 0.603 0.852 0.092 
   Mean difference 1.22 0.36 0.98 
   SE (95% CI) 2.3 (-3.4, 5.8) 1.9 (-3.4, 4.1) 0.6 (-0.2, 2.1) 
  
   Cell treatment effect 
with hyperlipidemia 
p value 0.430 0.738 0.067 
   Mean difference 1.95 0.67 1.09 
   SE (95% CI) 2.5 (-2.9, 6.8) 2.0 (-3.3, 4.6) 0.6 (-0.1, 2.3) 
  
   Cell treatment effect 
with MRI  
p value 0.604 0.887 0.028 
   Mean difference 1.26 -0.28 1.31 
   SE (95% CI) 2.4 (-3.5, 6.0) 2.0 (-4.2, 3.6) 0.6 (0.1, 2.5) 
  
   Cell treatment effect 
with age 
p value 0.006 0.029 0.702 
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   Mean difference 9.50 6.46 0.35 
   SE (95% CI) 3.4 (-2.8, 16.2) 2.9 (-0.7, 12.2) 0.9 (-1.5, 2.2) 
  
   Cell treatment effect 
with anterior infarction 
p value 0.737 0.448 0.074 
   Mean difference -1.11 -2.05 1.47 
   SE (95% CI) 3.3 (-7.6, 5.4) 2.7 (-7.4, 3.3) 0.8 (-0.1, 3.1) 
  
   Cell treatment effect 
with pre-end-diastolic 
volume 
p value 0.408 0.867 0.238 
   Mean difference 1.46 0.26 0.76 
   SE (95% CI) 1.8 (-2.0, 5.0) 1.5 (-2.8, 3.3) 0.6 (-0.5, 2.0) 
  
   Cell treatment effect 
with pre-ejection 
fraction* 
p value 0.418 0.793 0.304 
   Mean difference 1.69 0.51 0.76 
   SE (95% CI) 2.1 (-2.4, 5.8) 1.9 (-3.1, 4.3) 0.7 (-0.7, 2.2) 
    
Cell treatment effect 
with time to cell 
therapy+    
p value 0.649 0.938 0.435 
   Mean difference 7.78 8.92 -0.73 
   SE (95% CI) 4.9 (-1.9, 17.5) 4.0 (1.1, 16.8) 1.2 (-1.6, 3.1) 	  
MRI: magnetic resonance imaging, SE: standard error, CI: confidence interval.	  
*Sub-analysis between pre-EF groups are displayed in Table 4B.	  
+Effect of the covariate time to cell therapy in cell therapy group or randomization/sham intervention 
in controls post AMI	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Table 4A. Efficacy of cell therapy over time. No significant difference between the groups. 	  
Follow-up 
time 
 
Changes in  
end-diastolic 
volume 
Changes in  
end-systolic  
volume 
Changes in  
ejection 
fraction 
  
Mean±SD Mean±SD Mean±SD 
≤6 months Cell therapy (n=383) 10.2±37.3 2.2±32.6 3.9±10.3 
 
Controls (n=267) 8.4±28.8 0.31±26.2 2.9±9.6 
 
Difference in mean 
(95% CI)  1.9  (-3.4; 7.2) 1.9 (-2.9; 6.6) 0.9 (-0.6; 2.5) 
     >6-12 
months Cell therapy (n=241) 22.4±43.3 9.3±32.0 3.1±8.1 
 
Controls (n=173) 22.2±37.9 11.3±28.0 2.1±7.8 
 
Difference in mean 
(95% CI)  2.6 (-7.8; 8.3) -2.0 (-8.0; 4.0) 1.0 (-0.6; 2.5) 
 	  
SD: standard deviation, CI: confidence interval	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Table 4B. Impact of baseline ejection fraction on changes in left ventricular parameter. No 
significant difference between the groups. 	  
Baseline 
ejection 
fraction 
 
Changes in  
end-diastolic 
volume 
Changes in 
end-systolic 
volume 
Changes in  
ejection 
fraction 
  
Mean±SD Mean±SD Mean±SD 
     ≥50% Cell therapy (n=179) 14.6±35.2 6.3±26.5 2.2±8.3 
 
Controls (n=145) 10.6±29.5 4.0±19.8 0.7±8.7 
 
Difference in mean 
between cell therapy 
and controls (95% CI)  4.0 (-3.2; 11.2) 2.2 (-3.0; 7.5) 1.5 (-0.4; 3.3) 
     <50% Cell therapy (n=445) 15.2±42.1 4.5±34.7 4.1±9.9 
 
Controls (n=295) 15.5±35.2 4.9±30.5 3.5±9.0 
 
Difference in mean 
between cell therapy 
and controls (95% CI)   -0.3 (-6.1;5.6)  -0.5 (-5.4; 4.4) 0.6 (-0.8; 2.0) 
     ≥45% Cell therapy (n=267) 11.1±34.8 4.2±26.5 2.3±9.0 
 
Controls (n=212) 9.7±29.6 2.9±20.8 1.3±8.7 
 
Difference in mean 
between cell therapy 
and controls (95% CI)  1.4 (-4.5; 7.39) 1.3 (-3.1; 5.6) 1.0 (-0.6; 2.6) 
     <45% Cell therapy (n=357) 18.1±43.6 5.6±36.4 4.5±9.8 
 
Controls (n=228) 17.9±36.4 6.2±32.4 3.8±9.0 
 
Difference in mean 
between cell therapy 
and controls (95% CI)  0.2 (-6.7; 7.1)  -0.6 (-6.5; 5.2) 0.7 (-0.8; 2.3) 
     ≥40% Cell therapy (n=381) 12.1±36.8 4.0±27.1 2.6±9.2 
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Controls (n=292) 10.8±31.0 3.3±22.6 1.9±8.5 
 
Difference in mean 
between cell therapy 
and controls (95% CI)  1.4 (-3.9; 6.6) 0.7 (-3.1; 4.6) 0.8 (-0.6; 2.2) 
     <40% Cell therapy (n=243) 19.7±44.7 6.5±39.7 5.0±9.7 
 
Controls (n=148) 202±37.2 7.3±35.1 4.1±9.6 
 
Difference in mean 
between cell therapy 
and controls (95% CI)   -0.5 (-9.2; 8.2)  -0.8 (-8.7; 7.1) 0.9 (-1.1; 2.9) 
 	  
SD: standard deviation, CI: confidence interval	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!"#$%&'($)*+,+-+$
767 752 735 687 551 520 251 240 239 138 236 236 125 Number left 
0 11 22 28 40 54 92 102 103 104 106 106 107 
Number 
event 
485 477 464 392 343 314 161 159 157 155 154 153 152 Number left 
0 7 19 27 38 49 71 73 75 77 78 79 79 
Number 
event 
Cell-treated 
Controls 
./00$12/%&)3$
."'1%"04$
!"#$%&'($)*+,556$
7&8&%9$%&:"$;<=$.>$ !"##$%
&'()*+,%-.//%01.+'23% &'()*+,%-)40+)/,%
?@#A%/$5B$
Hazard
Ratio 
95% CI P value 
Type of 
treatment 0.815 0.574 - 1.157 0.253 
Gender 1.017 0.999 - 1.034 0.058 
DM 1.032 0.661 - 1.611 0.891 
Hypertension 0.922 0.591 - 1.438 0.720 
Hyperlipidaemia 1.268 0.873 - 1.842 0.213 
Age 1.032 0.718 - 1.483 0.863 
Baseline EDV 1.001 0.995 - 1.006 0.694 
Baseline EF 0.992 0.975 - 1.01 0.387 
CIRCRES/2014/304346/R3  35	  	  
	  	   	   !"#$%&'()'
*+,,-'
CIRCRES/2014/304346/R3  36	  	  
	  	   	  
!"##$%&"'()*$
!+,%'+#-$
767 754 746 701 567 473 272 270 270 269 268 268 267 Number left 
0 9 12 15 17 16 19 20 20 21 22 22 22 Number event 
485 479 472 399 362 342 182 181 181 180 177 177 176 Number left 
0 5 11 13 13 14 18 19 19 20 23 23 23 Number event 
Cell-treated 
Controls 
.+/$'(,0$)123245$
!"#$%&'&()*'&+$,-."&
/#0-1,2&3"44&$%",#56& /#0-1,2&3-7$,-42&
67/8'"$9:$
Hazard
Ratio 
95% CI P value 
Type of 
treatment 0.534 0.265 - 1.078 0.08 
Gender 1.047 1.01 - 1.086 0.012 
DM 1.101 0.46 - 2.635 0.829 
Hypertension 1.04 0.46 - 2.352 0.925 
Hyperlipidaemia 1.835 0.815 4.135 0.142 
Age 0.719 0.352 - 1.471 0.367 
Baseline EDV 0.998 0.989 - 1.007 0.673 
Baseline EF 0.964 0.932 - 0.996 0.028 
;(<('=$'(>+$45?$!@$
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!"##$%&"'()*$
!+,%'+#-$
767 757 743 642 560 531 255 244 243 243 242 242 241 Number left 
0 2 10 13 22 33 75 84 85 85 86 86 87 Number event 
485 464 453 377 334 323 166 165 163 163 163 162 162 Number left 
0 4 13 19 30 39 61 62 64 64 64 65 65 Number event 
Cell-treated 
Controls 
.+/$'(,0$)123422$
!"#$
%&'()*+$,-..$/0-*&12$ %&'()*+$,(3/*(.+$
56/7'"$8!$
Hazard
Ratio 
95% CI P value 
Type of 
treatment 0.831 0.565 - 1.222 0.346 
Gender 1.01 0.991 - 1.029 0.304 
DM 0.985 0.602 - 1.611 0.952 
Hypertension 0.871 0.527 - 1.44 0.589 
Hyperlipidaemia 1.184 0.786 - 1.783 0.418 
Age 1.157 0.774 - 1.73 0.476 
Baseline EDV 1.003 0.997 - 1.008 0.332 
Baseline EF 1 0.981 - 1.02 0.974 
9(:(';$'(<+$=>?$!@$
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